Bain Capital Life Sciences Raises Fourth Fund

Fund will invest in innovative life sciences companies that seek to improve the lives of patients with unmet needs

BOSTON – September 10, 2024 – Bain Capital Life Sciences (BCLS) has raised its fourth fund, with approximately $3 billion of total commitments.  The fund includes approximately $2.5 billion of outside commitments from existing and new investors.  Bain Capital partners, employees, and affiliates committed the balance of the fund, continuing the firm’s heritage of collectively being the largest investor across its funds.

The fund will draw on BCLS’ multi-decade investment experience to invest scale capital globally in transformative medicines, medical devices, diagnostics, and life sciences tools that have the potential to improve the lives of patients with unmet medical needs. The BCLS investment team includes more than 25 professionals, as well as a distinguished group of advisors, who together bring extensive private and public market investing experience, operating and consulting experience, and deep scientific and medical insights to each investment. These core capabilities are further complemented by the reach and resources of Bain Capital’s global platform.

Since its inception in 2016, BCLS has raised approximately $6.7 billion and invested in more than 70 companies that have initiated more than 100 clinical trials, achieved 16 regulatory authority approvals, and launched numerous products. 

About Bain Capital Life Sciences 
Bain Capital Life Sciences (www.baincapitallifesciences.com) was founded in 2016 and builds on Bain Capital’s forty-year history of healthcare and life sciences investing across private equity, public equity, credit, venture capital, and real estate. Bain Capital Life Sciences invests in biopharmaceutical, medical device, diagnostic, and life science tool companies across the globe, with a focus on companies that drive medical innovation to improve the lives of patients with unmet medical needs. The Bain Capital Life Sciences investment team has organically grown to more than 25 professionals with extensive public and private investing expertise, operating and consulting experience, and colleagues who bring deep scientific and medical insights.  The team’s differentiated skillset enables Bain Capital Life Sciences to invest scale capital and provide value-added strategic support to clinical and commercial-stage companies around critical phases of value creation.